The Federal Circuit heard oral arguments this week in Amgen v Sandoz, and the dispute centres on a seemingly simple question that goes to a key part of the Biologics Price Competition and Innovation Act: what does “shall” mean?
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
A&O Shearman and Fish & Richardson invested in German talent, meanwhile, major firms have assembled for an on the merits case pitting KeeeX against OpenAI and Adobe